
A retrospective, longitudinal cohort study was undertaken to analyze the effects of the FDA advisory on off-label topical calcineurin inhibitor (TCI) treatment practice patterns for infants with atopic dermatitis (<2 years of age). The results show a reduction in overall utilization of AD-related medications and reduced utilization of TCIs coupled with early introduction of topical corticosteroid treatment after the advisory compared to the period preceding the advisory.
